quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:15:11·653d
NEWSRelease
Ocuphire Pharma Inc. logo

Ocuphire Pharma Participates In ARVO SIG Panel And ASRS 42nd Annual Scientific Meeting To Highlight APX3330 For Diabetic Retinopathy

OCUP· Ocuphire Pharma Inc.
Health Care
Original source

Companies

  • OCUP
    Ocuphire Pharma Inc.
    Health Care

Recent analyst ratings

  • Nov 24UpdateHC Wainwright & Co.$26.00

Related

  • PR545d
    The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics
  • INSIDER546d
    SEC Form 4 filed by Director Graves Adrienne L
  • INSIDER546d
    Director Bennett Jean was granted 100,000 shares (SEC Form 4)
  • INSIDER546d
    SEC Form 3 filed by new insider Yerxa Benjamin R
  • INSIDER546d
    SEC Form 3 filed by new insider Graves Adrienne L
  • INSIDER546d
    SEC Form 3 filed by new insider Bennett Jean
  • SEC548d
    Ocuphire Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Completion of Acquisition or Disposition of Assets, Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
  • PR548d
    Ocuphire Pharma Announces Acquisition of Opus Genetics
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022